Healthcare
•3734 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3734)
| Company | Market Cap | Price |
|---|---|---|
|
ACLX
Arcellx, Inc.
Company's lead products are CAR-T cell therapies within oncology; direct product category is cell therapy.
|
$6.65B |
$115.06
-0.03%
|
|
PTGX
Protagonist Therapeutics, Inc.
Direct product category: PTGX's core business is peptide therapeutics.
|
$6.63B |
$106.06
+2.24%
|
|
HIMS
Hims & Hers Health, Inc.
Laboratory testing & advisory services core to in-house lab capabilities.
|
$6.56B |
$28.82
+6.78%
|
|
KYMR
Kymera Therapeutics, Inc.
Kymera's core offering is oral small molecule therapeutics designed to degrade disease-causing proteins (STAT6, IRAK4, IRF5) in immunology indications.
|
$6.31B |
$87.69
+1.80%
|
|
APGE
Apogee Therapeutics, Inc.
Directly develops and manufactures monoclonal antibody therapeutics (APG777, APG808, APG990).
|
$6.30B |
$92.13
+1.74%
|
|
LTH
Life Time Group Holdings, Inc.
MIORA longevity clinics and other healthcare services are provided as part of the ecosystem.
|
$6.30B |
$28.55
+3.07%
|
|
GRFS
Grifols, S.A.
Grifols operates as a large, global pharmaceutical company with a core focus on plasma-derived therapies.
|
$6.15B |
$7.50
-1.57%
|
|
PLXS
Plexus Corp.
Healthcare/Life Sciences end-market, with Plexus serving medical devices and related equipment through its engineering and manufacturing services.
|
$6.12B |
$228.75
+2.63%
|
|
BLCO
Bausch + Lomb Corporation
Ophthalmology Devices – direct manufacture and sale of eye-care surgical devices and related ophthalmic equipment.
|
$5.96B |
$16.80
+1.27%
|
|
CGON
CG Oncology, Inc. Common stock
CG Oncology is a biotech company focused on oncology therapies, with cretostimogene grenadenorepvec representing an oncology product in late-stage development.
|
$5.92B |
$73.42
+10.67%
|
|
RYTM
Rhythm Pharmaceuticals, Inc.
Rhythm's core business is developing and commercializing therapies for ultra-rare diseases (e.g., setmelanotide for MC4R pathway deficiencies, BBS), a hallmark of rare-disease biotech.
|
$5.92B |
$88.72
+0.69%
|
|
PTCT
PTC Therapeutics, Inc.
Sephience PKU and other PTC therapies are oral small-molecule drugs, a major product category for the company.
|
$5.82B |
$72.38
+0.95%
|
|
TFX
Teleflex Incorporated
Teleflex is a global medical device company designing, manufacturing, and selling single-use medical devices across critical care, surgical, and interventional markets.
|
$5.82B |
$131.54
+1.01%
|
|
AVTR
Avantor, Inc.
Avantor provides Laboratory Testing & Advisory Services, aligning with outsourced testing and regulatory support offerings.
|
$5.81B |
$8.52
+3.09%
|
|
BLTE
Belite Bio, Inc
Lead product Tinlarebant is an ophthalmic drug targeting retinal diseases (STGD1/GA).
|
$5.77B |
$165.16
+4.50%
|
|
ALKS
Alkermes plc
Direct product category encompassing Alkermes' oral small-molecule therapeutics, including LYBALVI.
|
$5.70B |
$34.52
+2.22%
|
|
CELC
Celcuity Inc.
Core asset gedatolisib targets oncology indications, placing Celcuity squarely in Biotech - Oncology.
|
$5.67B |
$122.44
-2.24%
|
|
SYRE
Spyre Therapeutics, Inc.
Spyre's pipeline comprises engineered monoclonal antibodies (SPY001/SPY002/SPY003) targeting α4β7, TL1A, and IL-23 for IBD and RA.
|
$5.67B |
$73.04
+4.79%
|
|
CDTX
Cidara Therapeutics, Inc.
CD388 is an antiviral small-molecule therapeutic targeting neuraminidase for universal influenza prevention and treatment.
|
$5.61B |
$221.39
+0.00%
|
|
TGTX
TG Therapeutics, Inc.
BRIUMVI is TG Therapeutics' flagship monoclonal antibody therapeutic (anti-CD20) for relapsing MS, the core product driving revenue and growth.
|
$5.61B |
$35.33
+2.99%
|
|
LNTH
Lantheus Holdings, Inc.
Directly produces radiopharmaceutical imaging agents and related therapies (e.g., PYLARIFY, DEFINITY) and maintains an expanding pipeline in this modality.
|
$5.56B |
$83.83
-0.11%
|
|
BRKR
Bruker Corporation
Bruker directly manufactures diagnostic instrumentation and analytical equipment such as MALDI Biotyper and other diagnostic/imaging instruments.
|
$5.54B |
$37.61
+3.01%
|
|
CRSP
CRISPR Therapeutics AG
CRISPR-based ex vivo gene-editing therapy CASGEVY is a gene therapy product.
|
$5.53B |
$58.01
+4.10%
|
|
CHE
Chemed Corporation
Chemed's VITAS Hospice provides direct home health and hospice care services.
|
$5.45B |
$384.77
+0.49%
|
|
VNT
Vontier Corporation
Repair Solutions includes diagnostic equipment launches for vehicle repair workflows.
|
$5.41B |
$37.32
+2.33%
|
|
ERAS
Erasca, Inc.
Erasa is a clinical-stage biotechnology company developing targeted cancer therapies, i.e., Biotech - Oncology.
|
$5.39B |
$19.00
+4.25%
|
|
CNTA
Centessa Pharmaceuticals plc
ORX750 is an orally administered, high-potency orexin receptor 2 (OX2R) agonist, fitting the 'Oral Small Molecule Therapeutics' category.
|
$5.33B |
$39.67
+0.35%
|
|
COGT
Cogent Biosciences, Inc.
Cogent's lead asset bezuclastinib and the described pipeline assets are primarily oral small-molecule tyrosine kinase inhibitors, i.e., Oral Small Molecule Therapeutics.
|
$5.30B |
$37.24
+2.92%
|
|
UNMA
Unum Group 6.250% JR NT58
Disability insurance is a core component of Unum's financial protection offerings in workplace benefits.
|
$5.29B |
$23.43
+0.34%
|
|
IPGP
IPG Photonics Corporation
IPG markets medical laser systems including thulium lasers for urology, fitting Medical Devices & Biometrics.
|
$5.27B |
$125.04
+3.59%
|
|
OSIS
OSI Systems, Inc.
Patient Monitoring represents next-generation monitoring platforms and solutions within healthcare offerings.
|
$5.26B |
$309.72
+2.87%
|
|
APLS
Apellis Pharmaceuticals, Inc.
SYFOVRE is an ophthalmic drug (intravitreal) approved for geographic atrophy, representing a direct product Apellis sells.
|
$5.17B |
$40.90
+0.06%
|
Showing page 7 of 38 (3734 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
